Ocumetics Technology Reports Attendance at ASCRS as Successful First-In-Human Trial Continues, No Material Change

(TheNewswire)

Key Highlights

• No material change: There is no material change in the business affairs ofOcumetics. 

• Attendance at ASCRS: Productive ASCRS meetings with major globalophthalmic leaders.  

• Clinical and development momentum:Feedback supported positive results from theFirst-in-Human (FIH) Group 1 study while the Company advances towardGroup 2 patient recruitment and upcoming surgeries.  

• Regulatory and commercializationpathway advancing: Discussions included FDAplanning, market potential, and capital needs, with ongoing follow-upengagement planned with industry partners. 

Calgary, Canada – April 14, 2026 -TheNewswire - OcumeticsTechnology Corp. (TSV:V OTC |OTCQB: OTCFF |FRA:2QBO) (“Ocumetics” or the “Company”),a leader in next generation ophthalmictechnology, is pleased to report highlyproductive meetings held in Washington, D.C. during the recentAmerican Society of Cataract and RefractiveSurgery (ASCRS) Annual Meeting, where theCompany engaged with industry leaders and senior leadership fromleading global ophthalmic organizations.

At the request of the Canadian Investment RegulatoryOrganization (CIRO) the Company announces that there is no materialchange in the business affairs of the Company.

Ocumetics’ meetings at ACRS focused on Ocumetics’continued clinical progress and strategic roadmap, with particularemphasis on the success of its First-in-Human (FIH) Group 1 study, itsnext-generation accommodating intraocular lens design and thebeginning phase of patient recruitment for its FIH Group 2study.

Key areas of discussion included:

• Positive clinical outcomes and patient satisfactionobserved in the FIH Group 1 study 

• Potential market impact of Ocumetics’ next-generationaccommodating intraocular lens design 

• Planning and timing for upcoming FIH Group 2surgeries 

• Regulatory strategy, including the pathway toward aU.S. FDA Investigational Device  

           Exemption (IDE) submission

• Capital requirements to support ongoing clinicaldevelopment and commercialization efforts 

Dean Burns, President & CEO of Ocumetics,commented: “Our discussions at ASCRS with several global leaders inophthalmology were extremely encouraging. The validation of ourFirst-In-Human Group 1 results, combined with meaningful dialoguearound our regulatory and clinical pathway, reinforces our belief thatOcumetics is well positioned to advance the next generation ofintraocular lens technology.”

As a result of these meetings, Ocumetics andparticipating organizations have agreed to continue engagement througha series of follow up discussions. These meetings will be conducted via virtual sessions and aligned with theachievement of key milestones, including the progression of additionalclinical studies and advancement of regulatory filings.

About Ocumetics

Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO)is a Canadian research and product development company that isdedicated to developing advanced vision correction solutions thatenhance the quality of life for patients.  Through innovativeresearch and development, Ocumetics aims to transform the field ofophthalmology with state-of-the-art intraocular lenses and othervision-enhancing technologies.

Ocumetics is in the first-in-human early feasibilitystudy phase of a game-changing technology for the ophthalmic industry. Ocumetics has developed an intraocular lens that fits within thenatural lens compartment of the eye, potentially to eliminate the needfor corrective lenses.  It is designed to allow the eye’s naturalmuscle activity to shift focus from distance to near, providing clearvision at all distances without the help of glasses or contact lenses,and without perceptible time lag.  

FOR FURTHER INFORMATION, PLEASECONTACT:

Dave Burwell

Director, Investor Relations        

dave.burwell@ocumetics.com

 (403) 410-7907       

Neither the TSXVenture Exchange nor its Regulation Services Provider (as that term isdefined in the policies of the TSX Venture Exchange) acceptsresponsibility for the adequacy or accuracy of this release.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKINGINFORMATION: This news release includes certain “forward-lookingstatements” under applicable Canadian securities legislation. Forward-looking statements include, but are not limited to,statements with respect to the commencement, timing and scope of theresearch and development to be conducted by the Company mentionedabove.  Forward-looking statements are necessarily based upon anumber of estimates and assumptions that, while considered reasonable,are subject to known and unknown risks, uncertainties, and otherfactors which may cause the actual results and future events to differmaterially from those expressed or implied by such forward-lookingstatements. Such factors include but are not limited to: operationalmatters, historical trends, current conditions and expected futuredevelopments, access to financing as well as other considerations thatare believed to be appropriate in the circumstances.  There can be noassurance that such statements will prove to be accurate, as actualresults and future events could differ materially from thoseanticipated in such statements. Accordingly, readers should not placeundue reliance on forward-looking statements.  The Company disclaimsany intention or obligation to update or revise any forward-lookingstatements, whether as a result of new information, future events orotherwise, except as required by law.

Copyright (c) 2026 TheNewswire - All rights reserved.